One key commonality observed in predicted GCN2-dependent cancers was enrichment in transforming growth factor β (TGF-β) signalling genes, which may point to a functional biomarker for targeting GCN2 dependent tumours. This evidence concerns the gene EIF2AK4 and cancer.